New cancer drugs often add little value for patients compared to standard treatments and are rarely worth the extra cost, according to two studies presented at ESMO Congress 2019. A trial that looked at new cancer drugs to treat solid tumours approved in France between 2004 to 2017 found that almost half had low added value scores ...
New cancer drugs are often not worth the cost
By Nicola Garrett
28 Sep 2019